Trial Profile

A 18-week, randomised, controlled, open-label, parallel-group study in adults with mild asthma, evaluating the efficacy and safety of Arnuity (fluticasone furoate) Ellipta 100mcg once daily plus Ventolin (salbutamol) 100mcg as needed and Flixotide (fluticasone propionate) Junior Accuhaler (FP) 100mcg twice daily plus Ventolin (salbutamol) 100mcg as needed compared with Symbicort (budesonide/formoterol) Turbuhaler 200/6mcg as needed.

Status: Not yet recruiting

Phase of Trial: Phase IV

Latest Information Update: 05 Sep 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Budesonide (Primary) ; Fluticasone furoate (Primary) ; Fluticasone propionate (Primary) ; Salbutamol (Primary) ; Budesonide/formoterol
Indications Asthma
Focus Therapeutic Use
Acronyms MIRSA

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com